Aikido Pharma Inc (NASDAQ: AIKI) Issues Update on Partnership With Cedars- Sinai Medical Centre

News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More.

Aikido Pharma Inc (NASDAQ: AIKI) recently issued an operational update to its shareholders by announcing the execution of a partnership. The company executed a partnership agreement with Cedars-Sinai Medical Centre to support innovative ideas and technologies.

The two institutions agreed to collaborate with each other’s talented teams to discover, protect and bear the costs of advertising innovative ideas. The agreement further stipulated that Aikido Pharma Inc would advertise the innovative ideas created by the hospital or any organization that supports it.

The hospital’s undertakings enabled it to receive an estimated 114 patients during the last quarter of 2021’s fiscal year. Cedars-Sinai also has at least 511 functioning technologies still under construction. Aikido Pharma recently stated that the hospital is an international institution thus possesses up-to-date technologies.

Aikido Pharma’s partnership with the hospital could increase its profit margins

The CEO of Aikido pharma, Anthony C. Hayes, stated that the company was excited to partner with the hospital. He further stated that both their teams have specialists in the areas of Intellectual property, which increases the institutions’ profit margin. In addition, the teams developed a strong portfolio that highlights their efficiency, which is observed in licensing and legal affairs. As a result, the institutions anticipate that the partnership will succeed, thus yielding results.

The company began in the mid-nineties, and it focuses on biotechnology advancements combining it with distinct expertise in antiviral therapeutics. Aikido Pharma also possesses intellectual protected technology developed by specialists who utilize the platform to create innovative ideas. Its portfolio consists of an award-winning team of study authors and Universities.

The company is planning to collaborate with the University of Maryland 

The company is planning to execute partnerships that, in turn, create a creative platform via powerful collaborations. The collaborations occur with institutions such as the University of Maryland in Baltimore.

The hospital is a non-profit organization that provides medical and educative solutions to patients with a diverse community. In addition, Cedars also provides remarkable patient consulting, medical studies, and various ventures that affect the community. The company had several locations in the U.S, such as Pasadena and New York.